Dashboard
Manage Tickers

ASND


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

raymond-james-initiates-coverage-on-ascendis-pharma-with-strong-buy-rating-announces-price-target-of-271
Raymond James Initiates Coverage On Ascend...
10/17/2025 15:32:22

Raymond James analyst Martin Auster initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Strong Buy rating and announc...

cantor-fitzgerald-maintains-overweight-on-ascendis-pharma-raises-price-target-to-254
Cantor Fitzgerald Maintains Overweight on ...
10/13/2025 13:37:25

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target fr...

jp-morgan-maintains-overweight-on-ascendis-pharma-raises-price-target-to-264
JP Morgan Maintains Overweight on Ascendis...
10/09/2025 12:50:01

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $26...

ascendis-pharma-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-transcon-cnp-as-a-treatment-for-children-with-achondroplasia
Ascendis Pharma Submits Marketing Authoris...
10/08/2025 20:03:36

COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a Mar...

what-does-the-market-think-about-ascendis-pharma-as
What Does the Market Think About Ascendis ...
09/29/2025 17:00:52

Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According t...

100-invested-in-ascendis-pharma-10-years-ago-would-be-worth-this-much-today
$100 Invested In Ascendis Pharma 10 Years ...
09/25/2025 23:00:33

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an...

ptc-therapeutics-could-challenge-biomarin-for-metabolic-disorder-treatment
PTC Therapeutics Could Challenge BioMarin ...
09/08/2025 17:56:24

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in...

100-invested-in-ascendis-pharma-10-years-ago-would-be-worth-this-much-today
$100 Invested In Ascendis Pharma 10 Years ...
09/08/2025 14:15:19

heres-how-much-100-invested-in-ascendis-pharma-10-years-ago-would-be-worth-today
Here's How Much $100 Invested In Ascendis ...
09/04/2025 20:30:39

ascendis-to-present-latest-achondroplasia-and-hypoparathyroidism-data-at-asbmr-2025
Ascendis To Present Latest Achondroplasia ...
09/02/2025 20:02:54

b-of-a-securities-maintains-buy-on-ascendis-pharma-raises-price-target-to-230
B of A Securities Maintains Buy on Ascendi...
09/02/2025 15:41:07

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $...

how-do-investors-really-feel-about-ascendis-pharma
How Do Investors Really Feel About Ascendi...
08/28/2025 17:00:46

if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-this-much-today
If You Invested $1000 In This Stock 10 Yea...
08/19/2025 15:00:31

jp-morgan-maintains-overweight-on-ascendis-pharma-raises-price-target-to-260
JP Morgan Maintains Overweight on Ascendis...
08/19/2025 14:17:08

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $25...

citigroup-maintains-buy-on-ascendis-pharma-raises-price-target-to-290
Citigroup Maintains Buy on Ascendis Pharma...
08/08/2025 22:47:08

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $243 to...

rbc-capital-maintains-outperform-on-ascendis-pharma-raises-price-target-to-230
RBC Capital Maintains Outperform on Ascend...
08/08/2025 17:22:18

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $21...

wedbush-maintains-outperform-on-ascendis-pharma-raises-price-target-to-220
Wedbush Maintains Outperform on Ascendis P...
08/08/2025 16:07:45

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $212 to...

ubs-maintains-buy-on-ascendis-pharma-raises-price-target-to-307
UBS Maintains Buy on Ascendis Pharma, Rais...
08/08/2025 15:54:26

UBS analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $306 to $307.

cantor-fitzgerald-maintains-overweight-on-ascendis-pharma-raises-price-target-to-203
Cantor Fitzgerald Maintains Overweight on ...
08/08/2025 15:07:28

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target fr...

stifel-maintains-buy-on-ascendis-pharma-raises-price-target-to-254
Stifel Maintains Buy on Ascendis Pharma, R...
08/08/2025 13:44:19

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $212 to $254.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION